Replies to post #155028 on Cytodyn Inc (CYDY)

[DonDonDonDon]

The term "data mining" is a tool shorts use to distract from positive results. You'll see it being used when trying to draw attention away from positive data.

Data mining is a term constantly used in the pharmaceutical industry. Academics love to use the phrase. The FDA wants your whole study to be a success, not a 16% slice. The FDA wants your primary endpoint to be met with statistical significance. The FDA does not like data mining. The FDA does not care if a 16% slice has a 9% benefit. That is beyond meaningless to them.

[djjazzyjeff]

So I guess the shorts prevented FDA from giving EUA? Because that's what those 'good results' got, another trial demanded. I love this, oh no it's just the shorts bashing to bring the price down. Bro, the FDA said no, you think they were shorting the stock or something? The results were bad, and Cytodyn went on a fishing expedition to find something ANYTHING to PR because they knew it was over. They can't afford another trial, let alone two. That's why no protocol submitted. No biotech company with good results fires out a barrage of hard to decipher PRs regarding results. And that two weeks of 'confidential talks' any insight into what could have possibly been confidential about 'you need another trial?' Just more Nader speak for 'hang on we need to cook something up.'

No matter what anyone says, not a single regulatory body on Earth recognizes leronlimab as an effective therapeutic. Sure, it's safe, have all the eINDs you want, but to market? Nah we'll pass it doesn't work thanks. That's not short sellers, that's just plain fact.